RT Journal Article SR Electronic T1 Elevated Neutrophil–to–Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3151 OP 3156 VO 38 IS 5 A1 GI YONG HWANG A1 DONG WON BAEK A1 HEE JEONG CHO A1 SOO JUNG LEE A1 YEE SOO CHAE A1 BYUNG WOOG KANG A1 IN HEE LEE A1 JONG GWANG KIM A1 AN NA SEO A1 HAN IK BAE A1 KI BUM PARK A1 JI YEON PARK A1 OH KYOUNG KWON A1 SEUNG SOO LEE A1 HO YOUNG CHUNG YR 2018 UL http://ar.iiarjournals.org/content/38/5/3151.abstract AB Background/Aim: This study investigated the clinical prognostic relevance of the neutrophil-to-lymphocyte ratio (NLR) in patients with human epidermal receptor 2 (HER2)-positive metastatic advanced gastric cancer (AGC) treated with combination chemotherapy including trastuzumab. Patients and Methods: This is a retrospective analysis of 73 patients diagnosed with metastatic AGC who were treated with trastuzumab combination chemotherapy. NLR was calculated as the neutrophil count divided by the lymphocyte count. A cut-off value of 3 was selected, which classified patients into two categories, low (≤3.0) or high (>3.0). Results: In the univariate analysis, the high-NLR patients showed a significantly shorter progression-free survival (PFS) and overall survival (OS) than the low-NLR patients (PFS, p=0.012, OS, p=0.047). In the multivariate analysis, the high NLR was independently associated with a shorter PFS (p=0.015) and OS (p=0.040). Conclusion: This study found that a high NLR was associated with a shorter PFS and OS in patients with HER2-positive gastric cancer treated with trastuzumab.